Sun Pharmaceutical Industries Secures Crucial Approval for Semaglutide in Brazil

Indian pharmaceutical giant Sun Pharmaceutical Industries has secured a crucial approval from the Brazilian Health Regulatory Agency – ANVISA – to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus.

Green Signal for Semaglutide in Brazil

This approval marks Sun Pharma’s second international approval for semaglutide, following a similar nod in South Africa earlier this month.

The development comes amidst a challenging period for another Indian pharmaceutical company, Dr Reddy’s Laboratories, which recently faced a setback in exports due to an “out of specification” issue with certain batches destined for Canada.

Partnership with Hypera Pharma

Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a pharmaceutical company in Brazil. The product will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once-weekly dosing.

Market Impact and Details

• The approval of semaglutide in Brazil reflects the strength of Sun Pharma’s development and manufacturing capabilities.
• The semaglutide injectable market in Brazil is approximately $413 million (IQVIA, MAT June 2026).
• Semaglutide is the active ingredient in Novo Nordisk’s obesity and diabetes drug Wegovy and Ozempic, respectively.

Key Takeaways

• Sun Pharma has secured approval from ANVISA to manufacture and market semaglutide injection in Brazil.
• The product will be launched in partnership with Hypera Pharma in the next few days.
• The semaglutide injectable market in Brazil is valued at approximately $413 million.

FAQs

What is semaglutide?

Semaglutide is a medication used to treat adults with inadequately controlled type 2 diabetes mellitus.

What is the significance of this approval for Sun Pharma?

This approval marks Sun Pharma’s second international approval for semaglutide and reflects the strength of the company’s development and manufacturing capabilities.

What is the market size for semaglutide in Brazil?

The semaglutide injectable market in Brazil is approximately $413 million (IQVIA, MAT June 2026).

Conclusion

Sun Pharma’s approval to manufacture and market semaglutide in Brazil marks a significant milestone for the company. As the pharmaceutical industry continues to evolve, it is essential for companies like Sun Pharma to stay ahead of the curve by investing in research and development. With this approval, Sun Pharma is well-positioned to capitalize on the growing demand for diabetes treatments in Brazil and beyond.